Stocks in play: Cardiol Therapeutics Inc.
Announced the publication of results from its Phase II ARCHER study in ESC Heart Failure, a journal of the European Society of Cardiology. Cardiol Therapeutics Inc. shares T.CRDL are trading down $0.01 at $1.42.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.